Leukemia, Luke Canley, Glivec discussed on The Peter Attia Drive
Now, of course, the answers are often not linear per se, but it gives you a route. I mean with come back to the metabolism study that we did Luke Canley that is a great example of taking a non linear problem and converting into a linear problem now to you about that in a second. But any time this was the case with diva to let's tell people what Glivec is. Yeah. Is a good example of a drug where we learned to target a mutant cancer, gene? Gene product. So in that case the cancer. It's a blood cancer called chronic myelogenous. Leukemia was also death sentence and also GI struggle tumor and yesterday to museum chronic myelogenous leukemia was a death sentence. People had to go. Through transplants. I've watched probably dozen in the pre glee Vic era doesn't patients die of chronic myelogenous. Leukemia, the complications of transplant like trained briefly as transplant and then all of a sudden through the work of many people, including Brian Drucker, drug was discovered before that scientists figured out based on very careful genetic analysis that the tumor was being driven by really the work of one, gene. And the gene was called VCR able it's it's an oncogene. It's not found enormous sales, but found in these cancer cells and the product of gene became like a like an engine like a manic engine that was driving these blood cells to go crazy and make more blood cells and proliferating in for the fruit. And it was this engine gone wide inside a cell and every time the sell us the question, should I divide rather than looking at its normal state or nutrients metabolic stated cetera. The only answer would ever get was from his engine saying, yes, go ahead. Make another sale divided cetera et cetera. So this was identified that the exhibit gene product was at the protein product of the gene was identified and then through an elaborate series of experiments in circumstances. Chemists found a way to actually jam the engine a one molecule human beings may we stitch this molecule together it's a remarkable achievement. And once the engine is jammed which suddenly turns out that the disease goes into mission. This was one of the first examples that others of so-called targeted therapy. Will you take you synthesize? A chemical to jam cancers engines in cancer specific way, doesn't affect normal cells. But what's interesting about that is that some people developed resistance because the engine cancer so Volve, and they find a way of resisting. But that was this tits. It becomes a linear problem. You figure out the mechanism the resistance, and you drive a second stake to Kansas heart, and when he becomes into that drive, a third stake and so forth. So all of a sudden the problem would seem like a big blank rock became a linear problem. So that that goes back and other. For example, of how that first stake or the for scramble really helps with the problem. And now immunotherapy MU logical therapy. The roadmap is much clearer. Why do some tumors responded by some don't respond? Visit a question of the environment that the two minutes sitting in is blood vessel is tumor cells immune cells, these are ons Rable questions. These are so called linear questions, but the first big step. Here was to define the problem. This is really a nice step off to exactly where I know. We wanna go, which is we've got surgical oncologists, medical oncologists radiation. Oncologists in many ways, a subset now of medical oncology, immuno based on college the work that you Lou and many others are now doing is potentially nother branch of college called metabolic on college. So you're beyond gracious in. You're suggesting I have even something to do with helping that evening turn into what sounds like a very productive collaboration between you and Lou and I'll be talking with Louis. Well when the next month, I'm sure but. Let's talk a little bit about what came out of that collaboration. And certainly bring it back to Ben Hopkins paper that was a nature. I believe was a NATO weeks ago. Yeah. So let's talk a little bit about the question. What were you trying to understand?.